Stemline Therapeutics Inc’s (NASDAQ:STML): Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of ...

Stemline Therapeutics, Inc. (NASDAQ:STML) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In the ...

Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required ...

It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do ...

Investors are always looking for stocks that are poised to beat at earnings season and Stemline Therapeutics, Inc. STML may be one such company. The firm has earnings coming up pretty soon, and events ...

Stemline Therapeutics (STML) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.92 per share a year ago. These ...

Investors certainly have to be happy with Stemline Therapeutics, Inc. (NASDAQ:STML) and its short term performance. After all, the stock has jumped by 40.3% in the past 4 weeks, and it is also above ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Stemline Therapeutics, Inc. has just filed its paperwork ...